Ixhalanex (Alprazolam)

Alprazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By increasing chloride ion flow into neurons, it produces a calming effect, decreasing neuronal excitability and alleviating anxiety symptoms.

The appropriate dose of Ixhalanex is determined by a qualified prescriber based on the individual’s clinical condition, age, and response to therapy. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

Alprazolam is classified as Pregnancy Category D, indicating potential risk to the fetus. It is generally avoided unless the therapeutic benefit justifies the risk. Alprazolam is also excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before use.

To request Ixhalanex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Ixhalanex (alprazolam) is a short‑acting benzodiazepine, offering rapid onset of anxiety relief compared with longer‑acting agents such as diazepam. Its potency allows lower dosing, but it also carries a higher risk of dependence, requiring careful monitoring.

Ixhalanex should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiration date.

Ixhalanex is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include respiratory depression, especially when combined with other CNS depressants, severe allergic reactions, profound sedation, dependence, withdrawal syndrome, and rare mood changes such as depression or suicidal thoughts. Immediate medical attention is required if any of these occur.

Ixhalanex is contraindicated in patients with known hypersensitivity to alprazolam or other benzodiazepines, those with acute narrow‑angle glaucoma, and individuals who are currently abusing alcohol or other central nervous system depressants. Caution is also advised for patients with severe hepatic impairment.